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Introduction Gamma-hydroxybutyric acid (GHB) is a neurotransmitter candidate found in the mammalian central nervous system (Maitre, 1997; Bernasconi et al., 1999) . GHB is released by depolarization in a calcium-dependent manner and possesses an active uptake mechanism.
The GHB system possesses high-affinity binding sites that are found predominantly in neurons of the cortex, striatum and hippocampus, with the highest density found in CA1 hippocampus (Hechler et al., 1987; Maitre, 1997) . The highest levels of endogenous GHB are found also in hippocampus, a brain region strongly implicated in memory formation and seizure activity (Rolls, 2000; McCormick and Contreras, 2001 ). Although GHB is closely related to GABA and can activate GABA B receptors at high doses, it appears to differ from the GABA transmitter system (Feigenbaum and Howard, 1996) . GHB has been used as a tool to induce a state of absence epilepsy, and several reports have suggested that GHB plays a role in absence seizures (Bernasconi et al., 1992; Banerjee et al., 1993; Maitre, 1997) . This effect, as well as a sedative action of GHB that has been widely used in general anesthesia, appears to arise from an interaction between the GABA and GHB transmitter systems (Maitre, 1997) . GHB also is increasingly utilized as a drug of abuse to produce euphoric and sedative states, with potential adverse effects that include memory loss, coma, seizure, and withdrawal symptoms (Galloway et al., 1997; Bernasconi et al., 1999) . On the other hand, GHB can reduce voluntary ethanol drinking and withdrawal symptoms in humans, and GHB is currently used to treat alcoholism (Gallimberti et al., 2000) .
In electrophysiological studies, a weak but consistent hyperpolarizing action of GHB has been described in CA1 hippocampal pyramidal neurons (Xie and Smart, 1992a) . GHB This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on May 19, 2004 as DOI: 10.1124 at ASPET Journals on November 4, 2017 jpet.aspetjournals.org Downloaded from JPET #69534 5 also inhibited neurons in the ventral tegmental area and neocortex (Madden and Johnson, 1998; Jensen and Mody, 2001 ) and concomitantly promoted oscillatory activity in substantia nigra and thalamocortical neurons (Engberg and Nissbrandt, 1993; Williams et al., 1995; Gervasi et al., 2003) . These effects were prevented by a GABA B receptor antagonist. GHB also reduced excitatory and inhibitory synaptic transmission via GABA B receptors in CA1 hippocampus (Xie and Smart, 1992b; Jensen and Mody, 2001 ), but other studies in this brain area showed that GHB elicited similar effects via presynaptic GHB (NCS-382 sensitive) receptors, not GABA B -receptors (Berton et al., 1999; Cammalleri et al., 2002) . A possible participation of GHB receptors in postsynaptic mechanisms has not been tested with the selective antagonist NCS-382 (Maitre et al., 1990) . Moreover, the postsynaptic conductances affected by GHB have not been characterized nor compared with GABA B -mediated effects.
GHB has emerged as a drug of abuse and is used at high, intoxicating doses. The precise postsynaptic target of GHB needs to be established to further ascertain its cellular action in hippocampus, a brain region that presents the highest levels of endogenous GHB and is implicated in memory formation and seizure activity. The differing results obtained with GHB in hippocampal synaptic studies and the incomplete characterization of the GHB postsynaptic action prompted us to further investigate GHB effects and compare them to those of a GABA B receptor agonist.
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Methods
Slice preparation. We prepared hippocampal slices as previously described (Schweitzer et al., 1993) . In brief, male Sprague-Dawley rats (100-150 g) were anesthetized with 3% halothane, decapitated and their brains rapidly removed and placed in ice-cold artificial cerebrospinal fluid (aCSF) gassed with 95% O 2 , 5% CO 2 . We isolated the hippocampus from the rest of the brain and cut transverse slices 350 µm thick with a McIlwain brain slicer, then incubated the slices in an interface configuration for about 30 min. Slices were then completely submerged and continuously superfused (2-4 ml/min) with warm (31 o C), gassed aCSF of the following composition (in mM): NaCl, 130; KCl, 3.5; NaH 2 PO 4 , 1.25; MgSO 4 , 1.5; CaCl 2 , 2.0; NaHCO 3 , 24; glucose, 10. Drugs were added to this aCSF in known concentrations. NCS-382 was a gift from Dr. G.L. Gessa, CGP 55845 was a gift from Drs. W.
Fröstl and A. Suter (Novartis Pharma). We obtained tetrodotoxin from CalbiochemNovabiochem (San Diego, CA). All other drugs were obtained from Sigma Chemical Corp (St. Louis, MO).
Electrophysiological recordings.
We recorded CA1 hippocampal pyramidal neurons with sharp micropipettes filled with 3M KCl using discontinuous voltage-clamp. The switching frequency was 3-4 kHz and we continuously monitored electrode settling time and capacitance neutralization at the headstage on a separate oscilloscope. Although whole-cell recordings with "patch" electrodes provide a better point clamp due to the low resistance of the electrodes, a major drawback resides in the washout (dialyse) of cytoplasmic components.
Because the conductances we studied do not require reaching much depolarized potentials, we used sharp electrodes to ensure we would not compromise drug effects that might be This article has not been copyedited and formatted. The final version may differ from this version. (Halliwell and Adams, 1982; Johnston and Brown, 1983) , but should be minimized by the study of relative conductance changes with superfusion of drugs to equilibrium conditions. We acquired data with an Axoclamp-2A preamplifier (Axon Instruments, Foster City, CA) and stored them for later analysis using pClamp software (Axon Instruments). Graphs were constructed using Origin software (OriginLab Corporation, Northampton, MA). We subjected data to a one-way ANOVA for repeated measures, with p < 0.05 considered statistically significant.
We routinely added 1 µM tetrodotoxin in the aCSF to block Na + channels and prevent synaptic transmission. Neurons were held near resting potential for stability but were briefly depolarized to deliver current-voltage (I-V) protocols, then repolarized near resting potential.
We generated I-V curves by holding neurons at -63.3 ± 0.3 mV (n = 41) and applying hyperpolarizing and depolarizing voltage steps (1.5 sec duration, 7 sec apart). Steady-state currents were measured at the end of the voltage steps. To study I h , we further analyzed the hyperpolarizing voltage steps (15 mV increments, 1.5 sec duration) obtained upon delivery of the I-V protocols. We quantified I h as the difference between the peak current of the relaxation (best fit using pClamp) observed at onset of hyperpolarizing voltage steps (following the capacitance artifact, no extrapolation) and the current measured at the end of the voltage step. These and other measures (e.g. current-voltage curves) were taken before 
Results
We recorded from 50 CA1 pyramidal neurons that had a mean resting membrane potential (RMP) of -68 ± 1 mV and action potential amplitude of 105 ± 1 mV. All experiments were conducted in the presence of 1 µM tetrodotoxin to prevent synaptic transmission.
GHB affects postsynaptic properties across the voltage range
GHB dose-dependently elicited an outward current associated with an increased input conductance at resting potential. Superfusion of 0.1 mM (n = 2) or 1 mM (n = 5) GHB had little or no effect on neuronal properties (Fig.1A ). On average, 1.0 mM GHB elicited an outward steady-state current of 12 ± 9 pA near RMP (n = 5). A higher concentration of GHB (10 mM) elicited a marked outward steady-state current associated with increased input conductance ( Fig 1B) . Current values fully recovered to control levels upon washout. On average, 10 mM GHB elicited an outward steady state current of 83 ± 16 pA at RMP (n = 15).
We generated current-voltage (I-V) relationships to study the effects of GHB on steady-state membrane properties at depolarized and hyperpolarized potentials. GHB elicited an outward current at depolarized potentials and an inward current at hyperpolarized potentials ( Fig and appeared to have characteristics similar to the component elicited by GHB. We then performed sequential applications of GHB and baclofen to investigate whether the two transmitters share similar sites of action. In this neuronal sample, 10 mM GHB alone elicited a steady-state current that had inward rectifying properties and reversed at -103 mV (n= 6, Fig. 3B ). After the GHB response reached equilibrium, we added 20 µM baclofen in the continued presence of GHB. Baclofen elicited a small additional effect that presented similar characteristics of voltage-dependency and reversed at -97 mV (Fig. 3B, 4A ). The GHB and baclofen effects were not significantly different (p > 0.05). Thus, GHB mostly occluded the baclofen effects suggesting that these compounds act through a common mechanism to inhibit CA1 pyramidal neurons.
We assessed the involvement of GABA B receptors by using receptor antagonists. The putative GHB receptor antagonist NCS-382 has been reported to prevent GHB effects in several preparations. NCS-382 applied alone (1 or 4 mM, n = 4) had no effect on membrane properties. In the presence of NCS-382, 10 mM GHB still elicited a pronounced outward current associated with increased input conductance, and further superfusion of baclofen This article has not been copyedited and formatted. The final version may differ from this version. elicited an additional outward current (Fig. 4A) . These results indicate that the GHB effect we observed is not mediated by NCS382-sensitive receptors. To ascertain that GHB acted via GABA B receptors, we applied GHB in slices pretreated with the selective GABA B receptor antagonist CGP 55845. Superfusion of 1 µM CGP 55845 alone did not alter neuronal properties but completely prevented the effects of 10 mM GHB (n = 5; Fig 4B) . The effect of GHB was blocked at all potentials (Fig. 4C) , demonstrating that GHB acted via GABA B receptors to inhibit CA1 neurons.
GHB and baclofen decrease the h-current
The I h is a mixed K + /Na + current active in the hyperpolarized range. This current is observed in CA1 pyramidal neurons as a slow relaxation that develops upon hyperpolarization, usually tested from a holding potential negative to -60 mV to avoid contamination by the M-current relaxation. We held neurons at -64 ± 1 mV (n = 14) and delivered 5 hyperpolarizing voltage steps (-15 mV increments) to study the modulation of I h by baclofen and GHB. Baclofen (20 µM) decreased I h , concomitant with an outward steadystate current around RMP and an inward steady-state current at hyperpolarized potentials (Fig. 5A ). On average, superfusion of baclofen significantly (p < 0.001, n = 14) decreased I h amplitude to 78 ± 3% of control with recovery to 92 ± 3% upon washout (Fig. 5B) . Thus baclofen concomitantly decreased I h and augmented a K + conductance.
We then assessed the effect of GHB on I h . We held neurons at -63 ± 1 mV (n = 17).
Application of 1 mM GHB had no significant effect on I h (97 ± 3% of control; p > 0.05, n = 5; data not shown), but 10 mM GHB altered steady-state currents and decreased I h in a manner similar to baclofen (Fig. 5C ). On average, GHB significantly (p < 0.001, n = 17) decreased I h to 83 ± 3% of control, with recovery to 94 ± 3% upon washout (Fig. 5D) . To ascertain that GHB decreased I h via GABA B receptors, we repeated the experiments in slices pre-treated with the selective GABA B receptor antagonist CGP 55845 (1 µM). With GABA B receptors blocked, 10 mM GHB did not significantly alter I h , which remained at 101 ± 2% of pre-drug level (p > 0.05, n = 5; Fig. 5E ). Thus, 10 mM GHB decreased I h via activation of GABA B receptors, an effect similar to that of baclofen.
We also investigated a possible effect of GHB on the M-current (I M ), a voltagedependent K + current active at depolarized potentials in CA1 pyramidal neurons. Neurons were held at -44 ± 1 mV and subjected to 5 hyperpolarizing voltage steps (-5 mV increments) to deactivate I M , which then appeared as a slow inward relaxation. Upon superfusion of 10 mM GHB, I M remained unaffected at 101 ± 5% of control (n = 6, data not shown).
Barium prevents GHB and baclofen effects
We further characterized GHB and baclofen effects by using the K + channel blocker barium. At a concentration of 200 µM, barium selectively inhibits inwardly rectifying K + conductances such as GIRK currents (Sodickson and Bean, 1996; Takigawa and Alzheimer, 1999) . In neurons pretreated with 200 µM barium, the effect of GHB on steady-state currents was mostly prevented. GHB only elicited a small steady-state outward component that showed no voltage-dependence and appeared to be carried by K + (n = 6; Fig. 6A ). Further addition of baclofen in the superfusate did not alter steady-state current values, indicating that barium also prevented baclofen effects. These results are consistent with the augmentation of a GIRK current by GHB and baclofen in control condition.
We assessed the modulation of I h by GHB and baclofen in the presence of barium.
The I h is insensitive to this ion (Pape, 1996) . Surprisingly, the diminution of I h by GHB or baclofen was largely prevented in neurons pre-exposed to 200 µM barium. While GHB and 
Characterization of the postsynaptic effects of GHB
Our results indicate that GHB alters the postsynaptic properties of CA1 pyramidal neurons by two ionic mechanisms. Current-voltage relationships show that the GHB-induced steady-state current reverses at -104 mV, suggesting that the overall effect is principally carried by K + . The inwardly rectifying profile of the GHB effect points to a GIRK current as the most likely candidate. In the presence of a low concentration of barium to selectively block GIRK currents (Takigawa and Alzheimer, 1999) , the GHB-elicited effect was markedly decreased, consistent with the involvement of a GIRK conductance.
GHB also decreased the hyperpolarization-activated cationic I h , an effect consistent with the reversal potential for the overall GHB effect (-104 mV) slightly more negative than the theoretical reversal for K + (-96 mV in our experimental conditions). Because I h is a mixed Na + /K + conductance that reverses at about -30 mV (Maccaferri et al., 1993) , a reduction of this current elicits an outward steady-state current at about -100 mV and therefore negatively shifts the reversal potential of the overall effect. Thus, GHB affects the postsynaptic properties of CA1 pyramidal neurons by two inhibitory mechanisms, the augmentation of an inwardly rectifying K + current (likely GIRK) and the decrease of I h .
GHB and baclofen effects are similar and occur via GABA B receptors
In this study, we compared the effects of GHB with those of the GABA B receptor agonist baclofen. Like GHB, baclofen elicited an outward current near resting potential and baclofen principally augments an inwardly rectifying K + conductance of the GIRK type (Lüscher et al., 1997) and concomitantly decreases I h (Takigawa and Alzheimer, 2003) . Thus GHB elicits baclofen-like postsynaptic effects in CA1 hippocampus. Accordingly, a selective GABA B receptor antagonist completely prevented GHB actions, conclusively involving GABA B receptors to mediate GHB effects. In contrast, the putative GHB receptor antagonist NCS-382 did not alter GHB or baclofen effects. Moreover, GHB mostly occluded the baclofen action, suggesting a common cellular mechanism for the two agonists. Notably, GHB is reportedly a weak (but selective) GABA B receptor agonist (Mathivet et al., 1997) , explaining the incomplete occlusion of the baclofen effect by GHB.
The implication of GABA B receptors to mediate GHB effects is in agreement with most electrophysiological studies (Xie and Smart, 1992a; Xie and Smart, 1992b; Engberg and Nissbrandt, 1993; Williams et al., 1995; Emri et al., 1996; Madden and Johnson, 1998; Jensen and Mody, 2001; Gervasi et al., 2003) . Still, GHB is believed to be a neurotransmitter with its own binding site different from GABA B receptors (Feigenbaum and Howard, 1996; Maitre, 1997) and GHB can alter synaptic activity with GABA B receptors blocked, an effect prevented by the putative GHB receptor antagonist NCS-382 (Berton et al., 1999; Cammalleri et al., 2002; Brancucci et al., 2004) . This latter action occurs at low concentrations of GHB, while the modulation of postsynaptic conductances requires high (millimolar) concentrations. GHB interaction with GABA B receptors may occur only at high doses, whereas GHB effects via a specific binding site take place at lower concentrations (Maitre, 1997; Bernasconi et al., 1999) . 
Modulation of the H-current
We did not observe a decrease of I h by GHB or baclofen in the presence of barium.
Such preventive effect of barium on the baclofen-elicited decrease of I h has been reported in substantia nigra and hippocampal neurons where it was concluded that the diminution of I h was secondary to the activation of GIRK currents (Watts et al., 1996; Takigawa and Alzheimer, 2003) . In ventral tegmental neurons, however, baclofen appeared to directly inhibit I h (Jiang et al., 1993) . In the CA1 hippocampal study, the authors argued that although the modulation of I h by baclofen was secondary to activation of GIRK, such shunting inhibition has important physiological significance (Takigawa and Alzheimer, 2003) . That is, the interplay between the activation of GIRK and the deactivation of I h dynamically alters the processing of incoming excitatory signals to modify the temporal integration of excitatory inputs. Thus, GHB acting at GABA B receptors may modulate the temporal integration of synaptic activity by affecting both GIRK and I h .
Interestingly, the GABA-like compound gabapentin also acts at GABA B receptors in hippocampus but augments I h (Ng et al., 2001; Surges et al., 2003) , and whereas gabapentin is used in the treatment of partial seizures, GHB is used to elicit absence seizures. In thalamic neurons, where I h regulates rhythmic activity (McCormick and Pape, 1990) , GHB promotes oscillatory cellular bursting via GABA B receptors (Williams et al., 1995) and administration of GHB in this region induces absence seizures (Snead, 1996) . A reduction of I h in inferior olivary neurons results in hyperpolarization and increased oscillations (Bal and McCormick, 1997) . Thus, GHB reduction of I h via GABA B receptors could modulate ensemble oscillations or seizure-like bursting. 
Pharmacological implications
Our results show that high concentrations of GHB activate GABA B receptor-mediated mechanisms, in accord with the current literature. The concentration of GHB that elicited a postsynaptic effect is higher than GHB levels described in normal physiological conditions (Maitre, 1997) . But most behavioral responses induced by GHB occur at high concentrations when GHB sites are saturated and GHB interacts with other systems, especially GABAergic transmission where GHB and GABA B receptors appear to be involved in a functional interplay (Bernasconi et al., 1999) . The postsynaptic effects of GHB that we characterized occur via GABA B receptors and parallel behavioral effects such as anesthesia and coma elicited by GABA B receptor agonists. Plasma concentrations in the low millimolar range induce moderate anesthesia in humans (Kleinschmidt et al., 1999) and reach several millimolars in abuse situations (Galloway et al., 1997) . GHB levels might be especially high in "acquaintance rape" settings where victims loose consciousness after intoxication. Thus, although this GHB concentration may not be physiological, it is consistent with pharmacological actions of GHB.
Further, the actual concentration of GHB surrounding the recorded neuron into the slice is likely lower than the nominal concentration delivered in the superfusion system, and active mechanisms of GHB uptake (Muller et al., 2002) may reduce the potency of GHB in the slice preparation. The relevance of high GHB concentrations has also been discussed in other studies (Madden and Johnson, 1998; Jensen and Mody, 2001) . Thus, while the physiological and therapeutic roles of GHB appear to involve high micromolar concentrations of GHB, the millimolar range tested in the present study compares to GHB levels obtained during anesthesia, abuse and intoxication in humans. The implication of did not prevent the outward current elicited by 10 mM GHB nor the additional effect elicited by further addition of baclofen. RMP was -69 mV. B. In the presence of 1 µM CGP 55845, a GABA B receptor antagonist, 10 mM GHB had no effect on membrane properties. RMP was -68 mV, holding potential was -68 mV. C. Net steady-state current elicited by 10 mM GHB in the presence of 1 µM CGP 55845 (n = 5). The GHB effect was prevented at all potentials. polynomial fit). On average, 10 mM GHB decreased I h by 17%. E. In the presence of 1 µM CGP 55845 to block GABA B receptors, 10 mM GHB had no effect on I h . at -64 mV, close to resting potential (average RMP was -68 mV). GHB had no effect at 1 mM, whereas 10 mM GHB or 15-20 µM baclofen elicited a pronounced outward current. The GHB effect persisted in the presence of the GHB receptor antagonist NCS-382 (1-4 mM), but was abolished by the GABA B receptor antagonist CGP 55845 (1 µM) or 200 µM barium to block inwardly rectifying K + currents. B. Percentile of I h decrease (pre-drug application is 100%) at about -135 mV (maximum I h activation). Again 1 mM GHB had no effect, but 10 mM GHB or 15-20 µM baclofen decreased I h . The effect of 10 mM GHB was unaffected by 1-4 mM NCS-382 but prevented by 1 µM CGP 55845 or 200 µM barium.
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